Picture of C4X Discovery Holdings logo

C4XD C4X Discovery Holdings Share Price

0.000.00%
gb flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapContrarian

Momentum

Relative Strength (%)
1m-36.67%
3m-44.55%
6m-52.32%
1yr-45.78%
Volume Change (%)
10d/3m-3.98%
Price vs... (%)
52w High-62.61%
50d MA-28.3%
200d MA-43.01%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital38.25%
Return on Equity55.38%
Operating Margin38.14%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Jul 202431st Jul 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of C4X Discovery Holdings EPS forecast chart

Profile Summary

C4X Discovery Holdings plc is a drug discovery company. The Company has a portfolio ranging from early-stage target opportunities to late-stage drug discovery programs. The Company has three commercially partnered programs with one candidate in clinical development. Its portfolio focuses on treatments for immuno-inflammatory diseases. The Company’s pipeline products include MALT-1 Inhibitor, a4B7 Integrin Inhibitor, IL-17A Inhibitor, NRF-2 Activator, and others. Its target identification platform (Taxonomy3) is used to analyze complex genetic datasets to identify and characterize drug target candidates. Taxonomy3 offers the potential for patient stratification in clinical trials, ensuring patient targeting and the potential for rescuing failed clinical trials or for drug repurposing. PatientSeek is its new platform that applies the mathematical approach of Taxonomy3 to stratify patients for treatments based on their genetics.

Directors

    Last Annual
    July 31st, 2023
    Last Interim
    January 31st, 2024
    Incorporated
    July 16th, 2014
    Public Since
    October 23rd, 2014
    No. of Employees
    49
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    gb flag iconLondon Stock Exchange
    Shares in Issue
    252,227,097

    C4XD Share Price Performance

    Upcoming Events for C4XD

    Similar to C4XD

    Picture of 4Basebio logo

    4Basebio

    gb flag iconLondon Stock Exchange

    Picture of Allergy Therapeutics logo

    Allergy Therapeutics

    gb flag iconLondon Stock Exchange

    Picture of Arecor Therapeutics logo

    Arecor Therapeutics

    gb flag iconLondon Stock Exchange

    Picture of Avacta logo

    Avacta

    gb flag iconLondon Stock Exchange

    Picture of Batm Advanced Communications logo

    Batm Advanced Communications

    gb flag iconLondon Stock Exchange

    FAQ